Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/3/2025

Pregabalin to Gabapentin Conversion

Introduction to Conversion

  • The recommended conversion ratio when transitioning from pregabalin to gabapentin is approximately 1:6, meaning 1 mg of pregabalin is roughly equivalent to 6 mg of gabapentin 1

Conversion Approach

  • When converting from pregabalin to gabapentin, a gradual transition is recommended to minimize breakthrough symptoms and adverse effects 1
  • The Mayo Clinic recommends a transition method using 50% of the original pregabalin dose plus 50% of the target gabapentin dose for 4 days, especially for patients sensitive to medication changes 1

Pharmacokinetic Considerations

  • Due to gabapentin's nonlinear pharmacokinetics, higher doses may have decreased bioavailability compared to pregabatin's linear pharmacokinetics 1
  • Pregabalin has a more rapid onset of action due to more efficient gastrointestinal absorption 1
  • Gabapentin requires a longer titration period (approximately 2 months) compared to pregabalin (approximately 4 weeks) to reach therapeutic effect 1
  • Both medications require dosage adjustments in patients with renal insufficiency 1

Dosing Strategy

  • Divide the total daily gabapentin dose into three times daily dosing due to its shorter half-life 2
  • For neuropathic pain management, gabapentin doses typically range from 100-1200 mg three times daily 2

Transition Monitoring

  • Monitor for breakthrough pain during the transition period, as gabapentin may take longer to reach full therapeutic effect 1

Discontinuation Considerations

  • Avoid abrupt discontinuation of pregabalin in patients who have been on high doses for extended periods 1

REFERENCES

1

Transitioning from Gabapentin to Pregabalin [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

2

adult cancer pain. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2010